Article · Wikipedia archive · Last revised Jul 19, 2026

AB-103

AB-103 is a minoxidil sulfotransferase stimulant which is under development for the treatment of alopecia as an adjunct to the hair loss drug minoxidil. It is used topically. The drug works by stimulating the enzyme SULT1A1 in hair follicles which converts minoxidil into its active form minoxidil sulfate and which has been found to predict minoxidil's clinical effectiveness. It was originated by Applied Biology and is under development by Safety Shot. As of February 2024, AB-103 is in phase 3 clinical trials for treatment of alopecia. It has been in this stage of development since at least April 2019, but there have been no more recent updates on its development since then. The chemical structure of AB-103 does not yet appear to have been disclosed.

Last revised
Jul 19, 2026
Read time
≈ 1 min
Length
244 w
Citations
11
Source
Wikipedia ↗
AB-103
Clinical data
Other namesAB103
Routes of
administration		Topical1
Drug classMinoxidil sulfotransferase stimulant

AB-103 is a minoxidil sulfotransferase stimulant which is under development for the treatment of alopecia (hair loss) as an adjunct to the hair loss drug minoxidil.1 It is used topically.1 The drug works by stimulating the enzyme SULT1A1 in hair follicles which converts minoxidil into its active form minoxidil sulfate and which has been found to predict minoxidil's clinical effectiveness.1234 It was originated by Applied Biology and is under development by Safety Shot.1 As of February 2024, AB-103 is in phase 3 clinical trials for treatment of alopecia.1 It has been in this stage of development since at least April 2019, but there have been no more recent updates on its development since then.1 The chemical structure of AB-103 does not yet appear to have been disclosed.1

See also

See also

References

References

  1. "AB 103". AdisInsight. 27 February 2024. Retrieved 23 October 2025.
  2. Goren A, Naccarato T (September 2018). "Minoxidil in the treatment of androgenetic alopecia". Dermatologic Therapy. 31 (5) e12686. doi:10.1111/dth.12686. PMID 30155952.
  3. Roberts J, Desai N, McCoy J, Goren A (2014). "Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil in the treatment of female androgenetic alopecia". Dermatologic Therapy. 27 (4): 252–254. doi:10.1111/dth.12130. PMID 24773771.
  4. Goren A, Shapiro J, Roberts J, McCoy J, Desai N, Zarrab Z, et al. (2015). "Clinical utility and validity of minoxidil response testing in androgenetic alopecia". Dermatologic Therapy. 28 (1): 13–16. doi:10.1111/dth.12164. PMID 25112173.